Title
Phil Pharmawealth, Inc. vs. Pfizer, Inc.
Case
G.R. No. 167715
Decision Date
Nov 17, 2010
Pfizer sued Phil Pharmawealth for patent infringement over "Unasyn." Patent expired, rendering injunctive relief moot. CA had jurisdiction over IPO orders. Forum shopping found; RTC case dismissed.
patent infringement
penicillin
sulbactam sodium
A

Case Summary (G.R. No. 75508)

Petitioner and Respondents — Roles and Allegations

Pfizer (respondents) alleged ownership of Philippine Letters Patent No. 21116 covering a method and specific compounds (including sulbactam and ampicillin sodium) and claimed that petitioner Phil Pharmawealth, Inc. submitted bids and offered sulbactam/ampicillin products to hospitals in the Philippines without Pfizer’s consent, thereby infringing the patent. Pfizer filed a complaint for patent infringement with the BLA-IPO and sought injunctive relief, damages, and forfeiture of infringing products.

Key Dates and Patent Term

Philippine Letters Patent No. 21116 was issued on July 16, 1987. Respondents admitted the patent’s term expired on July 16, 2004, consistent with the seventeen-year patent term provided by law in effect at issuance.

Applicable Law and Legal Framework

  • 1987 Philippine Constitution: Basis for judicial power to review acts of political departments and to adjudicate actual controversies.
  • Republic Act No. 165 (the statute governing the patent at the time of issuance): Section 37 grants patentees the exclusive right to make, use, and sell the patented article throughout the Philippines for the term of the patent; Section 21 establishes the seventeen-year term from issuance.
  • Intellectual Property Code (RA 8293): Section 7(b) vests the IPO Director General with exclusive appellate jurisdiction over decisions of the BLA-IPO (relevant to jurisdictional analysis).
  • Rules of Court provisions cited and applied: Section 4, Rule 129 (effect of admissions), Rule 58 (standards for temporary restraining orders and writs of preliminary injunction), Rule 65 (certiorari — Sections 1 and 4 governing certiorari relief and venue).
  • Rules and Regulations on Administrative Complaints for Violation of Laws Involving Intellectual Property Rights: Section 1(c), Rule 14 (interlocutory orders not appealable) and Section 3, Rule 1 (suppletory application of Rules of Court).

Factual Background and Preliminary Relief

Pfizer obtained a preliminary injunction from the BLA-IPO effective for ninety days. When respondents sought an extension of that preliminary injunction, the BLA-IPO denied the extension by order dated October 15, 2003; the BLA-IPO denied reconsideration on January 23, 2004. Respondents filed a special civil action for certiorari with the CA to challenge those administrative orders and sought reinstatement/extension of the injunction. While the CA matter was pending, respondents filed a separate civil action in the RTC for patent infringement and unfair competition, also seeking injunctive relief and damages. The RTC issued a temporary restraining order (conditioned on bond) and later a preliminary injunction. The CA issued an order approving respondents’ bond and a temporary restraining order on January 18, 2005. Petitioner moved to dismiss the CA petition for forum shopping; petitioner later argued the actions were moot and academic because the patent had expired on July 16, 2004.

Issues Presented to the Supreme Court

a) Whether injunctive relief can be issued based on a patent that has already lapsed;
b) Which tribunal has jurisdiction to review decisions/orders of the Director of Legal Affairs of the IPO (BLA-IPO) — the IPO Director General or the CA; and
c) Whether respondents committed forum shopping by filing proceedings with both the IPO/BLA-IPO and the RTC seeking essentially the same relief.

Analysis — Effect of Patent Expiration on Injunctive Relief

The Court held that a patentee’s exclusive rights exist only for the term of the patent. Under Section 37 of RA 165, the patentee’s exclusive right to make, use, and sell the patented product subsists only during the patent term. Because respondents admitted that Patent No. 21116 expired on July 16, 2004, the Court treated that admission as conclusive under Section 4, Rule 129 of the Rules of Court (an admission in the same case requires no proof unless shown to be a palpable mistake). With no remaining exclusive right after expiration, respondents lacked the clear and unmistakable right required to justify issuance or extension of injunctive relief. The Court applied the Rule 58 requisites for injunctive relief — existence of an entitlement to the relief and urgency to prevent serious damage — and concluded the CA’s issuance of a temporary restraining order on January 18, 2005, was improper because the underlying patent monopoly had already terminated and the underlying controversy concerning extension of the injunction was moot and academic.

Analysis — Jurisdiction to Review BLA-IPO Interlocutory Orders

Petitioner argued that under RA 8293 the IPO Director General has exclusive appellate jurisdiction over BLA-IPO decisions. The Court distinguished final decisions from interlocutory orders. RA 8293 confers appellate jurisdiction over decisions of the BLA-IPO, but the CA was asked to review an interlocutory order denying extension of a preliminary injunction, not a final decision. The implementing Rules and Regulations for administrative complaints explicitly provide that interlocutory orders are not appealable (Section 1(c), Rule 14) and do not prescribe a remedy for challenging such interlocutory orders. In the absence of an administrative appellate remedy, the Rules of Court apply suppletorily. Under those circumstances and consistent with Rule 65 provisions, the filing of a special civil action for certiorari with the CA was appropriate because there was no plain, speedy and adequate remedy in the ordinary course of law. The Court further reasoned that the question presented to the CA — whether the BLA-IPO committed grave abuse in denying the motion to extend the preliminary injunction — was a matter of pure law and therefore within the courts’ competence. The doctrine of primary jurisdiction did not preclude judicial review here because the matter did not require the specialized administrative discretion of the IPO; it was a legal question suited to judicial determination.

Analysis — Forum Shopping

The Court applied the established test for forum shopping: identity of parties (or representation of the same interests), identity of rights asserted and reliefs prayed for, and identity such that a judgment in one action would be res judicata in the other. The Court found substantial identity between the IPO/BLA-IPO complaint and the RTC complaint: both alleged infringement of Pfizer’s exclusive right to sell sulbactam/ampicillin products, and both sought substantially identical reliefs (temporary ex parte orders/TROs, preliminary injunctions, impounding or forfeiture of goods, and damages, culminating in permanent injunctions). The Court rejected respondents’ contention that the complaints were different because they invoked different patents; the decisive factor was identity of the acts complained of and the reliefs sought. Given the substantial identity of parties, causes, and relie

    ...continue reading

    Analyze Cases Smarter, Faster
    Jur helps you analyze cases smarter to comprehend faster, building context before diving into full texts. AI-powered analysis, always verify critical details.

    About Privacy Terms